Apo CIII inhibits the activation of lipoprotein lipase by Apo CII. Reduced levels of Apo CIII result in higher fatty acid uptake from plasma triglycerides into adipose tissue. Thus, Apo CIII is a potential target for treatment of obesity and insulin resistance. The normal plasma concentration of Apo CIII is 8-15mg per 100ml.
Source:
Human plasma (Shown to be non reactive for HBsAg, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.)
Storage and Stability:
Aliquot to avoid repeated freezing and thawing and store at -70 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.